Precipio, Inc. (NASDAQ:PRPO) Sees Large Decrease in Short Interest

Precipio, Inc. (NASDAQ:PRPO) was the recipient of a large decrease in short interest in the month of December. As of December 15th, there was short interest totaling 4,124 shares, a decrease of 44.2% from the November 30th total of 7,388 shares. Approximately 0.3% of the company’s stock are short sold. Based on an average daily trading volume, of 9,360 shares, the days-to-cover ratio is presently 0.4 days. Based on an average daily trading volume, of 9,360 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.3% of the company’s stock are short sold.

Precipio Stock Performance

Shares of Precipio stock opened at $23.50 on Friday. Precipio has a 1 year low of $3.90 and a 1 year high of $28.50. The firm’s 50-day moving average is $22.53 and its 200 day moving average is $17.83. The stock has a market cap of $41.13 million, a price-to-earnings ratio of -28.66 and a beta of 1.09. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.27 and a quick ratio of 1.10.

Precipio (NASDAQ:PRPO) last issued its earnings results on Friday, November 14th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter. The firm had revenue of $6.77 million during the quarter. Precipio had a negative return on equity of 10.07% and a negative net margin of 5.50%.

Analysts Set New Price Targets

A number of research analysts recently issued reports on PRPO shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Precipio in a research report on Wednesday, October 8th. Wall Street Zen lowered shares of Precipio from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. AMH Equity Ltd lifted its holdings in shares of Precipio by 370.1% during the third quarter. AMH Equity Ltd now owns 131,100 shares of the biotechnology company’s stock valued at $2,332,000 after purchasing an additional 103,210 shares in the last quarter. Evernest Financial Advisors LLC purchased a new stake in shares of Precipio during the 3rd quarter valued at about $374,000. Topline Capital Management LLC purchased a new stake in shares of Precipio during the 3rd quarter valued at about $1,158,000. Finally, Susquehanna International Group LLP bought a new stake in shares of Precipio in the third quarter worth approximately $194,000. Hedge funds and other institutional investors own 10.45% of the company’s stock.

Precipio Company Profile

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.